{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T10:45:45Z","timestamp":1649155545823},"reference-count":81,"publisher":"Bentham Science Publishers Ltd.","issue":"46","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,4,26]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Hyperkalemia is an important clinical problem that is associated with significant lifethreatening\ncomplications. Several conditions are associated with increased risk for hyperkalemia such as chronic\nkidney disease, diabetes mellitus, heart failure, and the use of renin-angiotensin-aldosterone system (RAAS)\ninhibitors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The purpose of this review is to present and critically discuss treatment options for the management of\nhyperkalemia.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>A comprehensive review of the literature was performed to identify studies assessing the drug-induced\nmanagement of hyperkalemia.\n<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The management of chronic hyperkalemia seems to be challenging and includes a variety of traditional\ninterventions, such as restriction in the intake of the dietary potassium, loop diuretics or sodium polystyrene sulfonate.\nIn the last few years, several new agents have emerged as promising options to reduce potassium levels in\nhyperkalemic patients. Patiromer and sodium zirconium cyclosilicate 9 (ZS-9) have been examined in hyperkalemic\npatients and were found to be efficient and safe. Importantly, the efficacy of these novel drugs might allow\nthe continuation of the use of RAAS inhibitors, morbidity- and mortality-wise beneficial class of drugs in the\nsetting of chronic kidney disease and heart failure.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Data support that the recently emerged patiromer and ZS-9 offer significant hyperkalemia-related\nbenefits. Larger trials are needed to unveil the impact of these drugs in other patients\u2019 subpopulations, as well.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612825666190306162339","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T11:33:12Z","timestamp":1552044792000},"page":"5542-5547","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia"],"prefix":"10.2174","volume":"24","author":[{"given":"Vasilios G.","family":"Athyros","sequence":"first","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros G.","family":"Sachinidis","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Zografou","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisavet","family":"Simoulidou","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Piperidou","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikiforos","family":"Stavropoulos","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asterios","family":"Karagiannis","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","volume":"351","author":"Palmer B.F.","year":"2004","unstructured":"Palmer BF. N Engl J Med, Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system., 2004, 351, 585-592,","journal-title":"N Engl J Med"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/j.ajkd.2010.01.020","volume":"56","author":"Palmer B.F.","year":"2010","unstructured":"Palmer BF. Am J Kidney Dis, A physiologic-based approach to the evaluation of a patient with hyperkalemia., 2010, 56, 387-393,","journal-title":"Am J Kidney Dis"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"e002011","DOI":"10.1136\/bmjopen-2012-002011","volume":"2","author":"Fleet J.L.","year":"2012","unstructured":"Fleet JL, Shariff SZ, Gandhi S, Weir MA, Jain AK, Garg AX. BMJ Open, Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission., 2012, 2, e002011-,","journal-title":"BMJ Open"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1532-5415.2011.03818.x","volume":"60","author":"Drawz P.E.","year":"2012","unstructured":"Drawz PE, Babineau DC, Rahman M. J Am Geriatr Soc, Metabolic complications in elderly adults with chronic kidney disease., 2012, 60, 310-315,","journal-title":"J Am Geriatr Soc"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2215\/CJN.01150112","volume":"7","author":"Sarafidis P.A.","year":"2012","unstructured":"Sarafidis PA, Blacklock R, Wood E. Clin J Am Soc Nephrol, Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic., 2012, 7, 1234-1241,","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ejim.2009.07.002","volume":"20","author":"Drion I.","year":"2009","unstructured":"Drion I, Joosten H, Dikkeschei LD, Groenier KH, Bilo HJ. Eur J Intern Med, eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population., 2009, 20, 722-727,","journal-title":"Eur J Intern Med"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","volume":"169","author":"Einhorn L.M.","year":"2009","unstructured":"Einhorn LM, Zhan M, Hsu VD. Arch Intern Med, The frequency of hyperkalemia and its significance in chronic kidney disease., 2009, 169, 1156-1162,","journal-title":"Arch Intern Med"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"c8","DOI":"10.1159\/000329511","volume":"120","author":"Hayes J.","year":"2012","unstructured":"Hayes J, Kalantar-Zadeh K, Lu JL, Turban S, Anderson JE, Kovesdy CP. Nephron Clin Pract, Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race., 2012, 120, c8-c16,","journal-title":"Nephron Clin Pract"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2215\/CJN.05850809","volume":"5","author":"Korgaonkar S.","year":"2010","unstructured":"Korgaonkar S, Tilea A, Gillespie BW. Clin J Am Soc Nephrol, Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study., 2010, 5, 762-769,","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ajh\/hps038","volume":"26","author":"Susantitaphong P.","year":"2013","unstructured":"Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL. Am J Hypertens, Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis., 2013, 26, 424-441,","journal-title":"Am J Hypertens"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrneph.2014.168","volume":"10","author":"Kovesdy C.P.","year":"2014","unstructured":"Kovesdy CP. Nat Rev Nephrol, Management of hyperkalaemia in chronic kidney disease., 2014, 10, 653-662,","journal-title":"Nat Rev Nephrol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/0885066605278969","volume":"20","author":"Evans K.J.","year":"2005","unstructured":"Evans KJ, Greenberg A. J Intensive Care Med, Hyperkalemia: a review., 2005, 20, 272-290,","journal-title":"J Intensive Care Med"},{"key":"ref=13","author":"","year":"2013","unstructured":". , KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney inter , 3: 1-150., 2013"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"James P.A.","year":"2014","unstructured":"James PA, Oparil S, Carter BL. JAMA, 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)., 2014, 311, 507-520,","journal-title":"JAMA"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"McMurray J.J.","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD. Eur Heart J, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC., 2012, 33, 1787-1847,","journal-title":"Eur Heart J"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"Yancy C.W.","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B. J Am Coll Cardiol, 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines., 2013, 62, e147-e239,","journal-title":"J Am Coll Cardiol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/j.1755-5922.2010.00258.x","volume":"30","author":"Raebel M.A.","year":"2012","unstructured":"Raebel MA. Cardiovasc Ther, Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers., 2012, 30, e156-e166,","journal-title":"Cardiovasc Ther"},{"key":"ref=18","first-page":"S1","volume":"43","author":"","year":"2004","unstructured":". Am J Kidney Dis, K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease., 2004, 43, S1-S290,","journal-title":"Am J Kidney Dis"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"Pitt B.","year":"2011","unstructured":"Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ. Eur Heart J, Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial., 2011, 32, 820-828,","journal-title":"Eur Heart J"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.2174\/1381612823666170206154706","volume":"23","author":"Faselis C.","year":"2017","unstructured":"Faselis C, Boutari C, Doumas M, Imprialos K, Stavropoulos K, Kokkinos P. Curr Pharm Des, Novel drugs for hypertension and heart failure: struggling for a place under the sun., 2017, 23, 1540-1550,","journal-title":"Curr Pharm Des"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.07821109","volume":"5","author":"Weir M.R.","year":"2010","unstructured":"Weir MR, Rolfe M. Clin J Am Soc Nephrol, Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors., 2010, 5, 531-548,","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","volume":"34","author":"Lazich I.","year":"2014","unstructured":"Lazich I, Bakris GL. Semin Nephrol, Prediction and management of hyperkalemia across the spectrum of chronic kidney disease., 2014, 34, 333-339,","journal-title":"Semin Nephrol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"Pitt B.","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ. N Engl J Med, The effect of spironolactone on morbidity and mortality in patients with severe heart failure., 1999, 341, 709-717,","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"Williams B.","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S. Lancet, Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial., 2015, 386, 2059-2068,","journal-title":"Lancet"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","volume":"31","author":"Oxlund C.S.","year":"2013","unstructured":"Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. J Hypertens, Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial., 2013, 31, 2094-2102,","journal-title":"J Hypertens"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"Juurlink D.N.","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS. N Engl J Med, Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study., 2004, 351, 543-551,","journal-title":"N Engl J Med"},{"key":"ref=27","first-page":"F257","volume":"240","author":"Bia M.J.","year":"1981","unstructured":"Bia MJ, DeFronzo RA. Am J Physiol, Extrarenal potassium homeostasis., 1981, 240, F257-F268,","journal-title":"Am J Physiol"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/MNH.0b013e32833ce6d5","volume":"19","author":"Toto R.D.","year":"2010","unstructured":"Toto RD. Curr Opin Nephrol Hypertens, Aldosterone blockade in chronic kidney disease: can it improve outcome?, 2010, 19, 444-449,","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"Mehdi U.F.","year":"2009","unstructured":"Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. J Am Soc Nephrol, Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy., 2009, 20, 2641-2650,","journal-title":"J Am Soc Nephrol"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","volume":"29","author":"Nielsen S.E.","year":"2012","unstructured":"Nielsen SE, Persson F, Frandsen E. Diabet Med, Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study., 2012, 29, e184-e190,","journal-title":"Diabet Med"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1440-1681.2006.04390.x","volume":"33","author":"Ogawa S.","year":"2006","unstructured":"Ogawa S, Takeuchi K, Mori T, Nako K, Ito S. Clin Exp Pharmacol Physiol, Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor., 2006, 33, 477-479,","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","volume":"28","author":"Rossing K.","year":"2005","unstructured":"Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Diabetes Care, Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study., 2005, 28, 2106-2112,","journal-title":"Diabetes Care"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2310\/JIM.0b013e31816d78e9","volume":"56","author":"Saklayen M.G.","year":"2008","unstructured":"Saklayen MG, Gyebi LK, Tasosa J, Yap J. J Investig Med, Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial., 2008, 56, 714-719,","journal-title":"J Investig Med"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","volume":"68","author":"Schjoedt K.J.","year":"2005","unstructured":"Schjoedt KJ, Rossing K, Juhl TR. Kidney Int, Beneficial impact of spironolactone in diabetic nephropathy., 2005, 68, 2829-2836,","journal-title":"Kidney Int"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","volume":"70","author":"Schjoedt K.J.","year":"2006","unstructured":"Schjoedt KJ, Rossing K, Juhl TR. Kidney Int, Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy., 2006, 70, 536-542,","journal-title":"Kidney Int"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"van den Meiracker A.H.","year":"2006","unstructured":"van den Meiracker AH, Baggen RG, Pauli S. J Hypertens, Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function., 2006, 24, 2285-2292,","journal-title":"J Hypertens"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/ndt\/gft281","volume":"28","author":"Esteghamati A.","year":"2013","unstructured":"Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M. Nephrol Dial Transplant, Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial., 2013, 28, 2823-2833,","journal-title":"Nephrol Dial Transplant"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1470320313481485","volume":"16","author":"Momeni A.","year":"2015","unstructured":"Momeni A, Behradmanesh MS, Kheiri S, Karami Horestani M. J Renin Angiotensin Aldosterone Syst, Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy., 2015, 16, 113-118,","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=39","first-page":"648","volume":"4","author":"Ziaee A.","year":"2013","unstructured":"Ziaee A, Abbas Vaezi A, Oveisi S, Javadi A, Hashemipour S, Kazemifar AM. Caspian J Intern Med, Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: A pilot randomized clinical trial., 2013, 4, 648-653,","journal-title":"Caspian J Intern Med"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2215\/CJN.07460713","volume":"9","author":"Van Buren P.N.","year":"2014","unstructured":"Van Buren PN, Adams-Huet B, Nguyen M, Molina C, Toto RD. Clin J Am Soc Nephrol, Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy., 2014, 9, 295-301,","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s10157-015-1106-2","volume":"19","author":"Kato S.","year":"2015","unstructured":"Kato S, Maruyama S, Makino H. Clin Exp Nephrol, Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial., 2015, 19, 1098-1106,","journal-title":"Clin Exp Nephrol"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02333-6","volume":"15","author":"Epstein M.","year":"2005","unstructured":"Epstein M, Buckalew V, Martinez F. Am J Hypertens, Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination in diabetic hypertensives with microalbuminuria., 2005, 15, 24A-,","journal-title":"Am J Hypertens"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"Bakris G.L.","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC. JAMA, Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial., 2015, 314, 884-894,","journal-title":"JAMA"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/jdi.12629","volume":"8","author":"Sun L.J.","year":"2017","unstructured":"Sun LJ, Sun YN, Shan JP, Jiang GR. J Diabetes Investig, Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy., 2017, 8, 609-618,","journal-title":"J Diabetes Investig"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.115.04889","volume":"66","author":"Pitt B.","year":"2015","unstructured":"Pitt B, Bakris GL. Hypertension, New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future., 2015, 66, 731-738,","journal-title":"Hypertension"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1097\/CCM.0b013e31818f222b","volume":"36","author":"Weisberg L.S.","year":"2008","unstructured":"Weisberg LS. Crit Care Med, Management of severe hyperkalemia., 2008, 36, 3246-3251,","journal-title":"Crit Care Med"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.resuscitation.2005.11.002","volume":"70","author":"Alfonzo A.V.","year":"2006","unstructured":"Alfonzo AV, Isles C, Geddes C, Deighan C. Resuscitation, Potassium disorders--clinical spectrum and emergency management., 2006, 70, 10-25,","journal-title":"Resuscitation"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.kint.2015.11.018","volume":"89","author":"Sterns R.H.","year":"2016","unstructured":"Sterns RH, Grieff M, Bernstein PL. Kidney Int, Treatment of hyperkalemia: something old, something new., 2016, 89, 546-554,","journal-title":"Kidney Int"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/jhm.977","volume":"7","author":"Schafers S.","year":"2012","unstructured":"Schafers S, Naunheim R, Vijayan A, Tobin G. J Hosp Med, Incidence of hypoglycemia following insulin-based acute stabilization of hyperkalemia treatment., 2012, 7, 239-242,","journal-title":"J Hosp Med"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1503\/cmaj.100461","volume":"182","author":"Elliott M.J.","year":"2010","unstructured":"Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR. CMAJ, Management of patients with acute hyperkalemia., 2010, 182, 1631-1635,","journal-title":"CMAJ"},{"key":"ref=51","first-page":"CD003235","author":"Mahoney B.A.","year":"2005","unstructured":"Mahoney BA, Smith WA, Lo DS, Tsoi K, Tonelli M, Clase CM. Cochrane Database Syst Rev, Emergency interventions for hyperkalaemia., 2005, 182, CD003235-,","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ki.1992.51","volume":"41","author":"Blumberg A.","year":"1992","unstructured":"Blumberg A, Weidmann P, Ferrari P. Kidney Int, Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure., 1992, 41, 369-374,","journal-title":"Kidney Int"},{"key":"ref=53","first-page":"297","volume":"17","author":"Gutierrez R.","year":"1991","unstructured":"Gutierrez R, Schlessinger F, Oster JR, Rietberg B, Perez GO. Miner Electrolyte Metab, Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage renal disease., 1991, 17, 297-302,","journal-title":"Miner Electrolyte Metab"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1681\/ASN.2010010079","volume":"21","author":"Sterns R.H.","year":"2010","unstructured":"Sterns RH, Rojas M, Bernstein P, Chennupati S. J Am Soc Nephrol, Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?, 2010, 21, 733-735,","journal-title":"J Am Soc Nephrol"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.phrs.2016.07.032","volume":"118","author":"Pitt B.","year":"2017","unstructured":"Pitt B, Rossignol P. Pharmacol Res, Potassium lowering agents: Recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia., 2017, 118, 2-4,","journal-title":"Pharmacol Res"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM196101192640303","volume":"264","author":"Scherr L.","year":"1961","unstructured":"Scherr L, Ogden DA, Mead AW, Spritz N, Rubin AL. N Engl J Med, Management of hyperkalemia with a cation-exchange resin., 1961, 264, 115-119,","journal-title":"N Engl J Med"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0140-6736(53)90465-6","volume":"265","author":"Evans B.M.","year":"1953","unstructured":"Evans BM, Jones NC, Milne MD, Yellowlees H. Lancet, Ion-exchange resins in the treatment of anuria., 1953, 265, 791-795,","journal-title":"Lancet"},{"key":"ref=58","author":"","year":"2011","unstructured":". , Administration UFaD. Kayexalate (sodium polystyrene sulfonate)powder., , 2011"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"264.e9","DOI":"10.1016\/j.amjmed.2012.08.016","volume":"126","author":"Harel Z.","year":"2013","unstructured":"Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Am J Med, Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review., 2013, 126, 264.e9-264.e24,","journal-title":"Am J Med"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/clc.20987","volume":"35","author":"Chernin G.","year":"2012","unstructured":"Chernin G, Gal-Oz A, Ben-Assa E. Clin Cardiol, Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy., 2012, 35, 32-36,","journal-title":"Clin Cardiol"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2215\/CJN.03640415","volume":"10","author":"Lepage L.","year":"2015","unstructured":"Lepage L, Dufour AC, Doiron J. Clin J Am Soc Nephrol, Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD., 2015, 10, 2136-2142,","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.2146\/news150079","volume":"72","author":"Thompson C.A.","year":"2015","unstructured":"Thompson CA. Am J Health Syst Pharm, FDA approves patiromer for nonemergent hyperkalemia., 2015, 72, 2006-,","journal-title":"Am J Health Syst Pharm"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1074248416629549","volume":"21","author":"Li L.","year":"2016","unstructured":"Li L, Harrison SD, Cope MJ. J Cardiovasc Pharmacol Ther, Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia., 2016, 21, 456-465,","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1681\/ASN.2010010079","volume":"21","author":"Sterns R.H.","year":"2010","unstructured":"Sterns RH, Rojas M, Bernstein P, Chennupati S. J Am Soc Nephrol, Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?, 2010, 21, 733-735,","journal-title":"J Am Soc Nephrol"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF02233563","volume":"11","author":"Fordtran J.S.","year":"1966","unstructured":"Fordtran JS, Locklear TW. Am J Dig Dis, Ionic constituents and osmolality of gastric and small-intestinal fluids after eating., 1966, 11, 503-521,","journal-title":"Am J Dig Dis"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"Weir M.R.","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA. N Engl J Med, Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors., 2015, 372, 211-221,","journal-title":"N Engl J Med"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","volume":"314","author":"Bakris G.L.","year":"2015","unstructured":"Bakris GL, Pitt B, Weir MR. JAMA, Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial., 2015, 314, 151-161,","journal-title":"JAMA"},{"key":"ref=68","author":"Fulton T.B.","year":"","unstructured":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. , , Accessed July 21, 2018."},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"e114686","DOI":"10.1371\/journal.pone.0114686","volume":"9","author":"Stavros F.","year":"2014","unstructured":"Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS. PLoS One, Characterization of structure and function of ZS-9, a K+ selective ion trap., 2014, 9, e114686-,","journal-title":"PLoS One"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","volume":"314","author":"Bakris G.L.","year":"2015","unstructured":"Bakris GL, Pitt B, Weir MR. JAMA, Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial., 2015, 314, 151-161,","journal-title":"JAMA"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/ki.2015.270","volume":"88","author":"Bushinsky D.A.","year":"2015","unstructured":"Bushinsky DA, Williams GH, Pitt B. Kidney Int, Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia., 2015, 88, 1427-1433,","journal-title":"Kidney Int"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"Weir M.R.","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA. N Engl J Med, Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors., 2015, 372, 211-221,","journal-title":"N Engl J Med"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","volume":"17","author":"Pitt B.","year":"2015","unstructured":"Pitt B, Bakris GL, Bushinsky DA. Eur J Heart Fail, Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors., 2015, 17, 1057-1065,","journal-title":"Eur J Heart Fail"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/HJH.0000000000001278","volume":"35","author":"Weir M.R.","year":"2017","unstructured":"Weir MR, Mayo MR, Garza D. J Hypertens, Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics., 2017, 35, S57-S63,","journal-title":"J Hypertens"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.kint.2016.04.019","volume":"90","author":"Weir M.R.","year":"2016","unstructured":"Weir MR, Bakris GL, Gross C. Kidney Int, Treatment with patiromer decreases aldosterone in\u00a0patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors., 2016, 90, 696-704,","journal-title":"Kidney Int"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2215\/CJN.01170216","volume":"11","author":"Bushinsky D.A.","year":"2016","unstructured":"Bushinsky DA, Spiegel DM, Gross C. Clin J Am Soc Nephrol, Effect of Patiromer on Urinary Ion Excretion in Healthy Adults., 2016, 11, 1769-1776,","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"Pitt B.","year":"2011","unstructured":"Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ. Eur Heart J, Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial., 2011, 32, 820-828,","journal-title":"Eur Heart J"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"Packham D.K.","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT. N Engl J Med, Sodium zirconium cyclosilicate in hyperkalemia., 2015, 372, 222-231,","journal-title":"N Engl J Med"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"Kosiborod M.","year":"2014","unstructured":"Kosiborod M, Rasmussen HS, Lavin P. JAMA, Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial., 2014, 312, 2223-2233,","journal-title":"JAMA"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","volume":"17","author":"Anker S.D.","year":"2015","unstructured":"Anker SD, Kosiborod M, Zannad F. Eur J Heart Fail, Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial., 2015, 17, 1050-1056,","journal-title":"Eur J Heart Fail"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ki.2014.382","volume":"88","author":"Ash S.R.","year":"2015","unstructured":"Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS. Kidney Int, A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient., 2015, 88, 404-411,","journal-title":"Kidney Int"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T21:43:44Z","timestamp":1558820624000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170507\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":81,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2019,4,26]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190306162339","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}